{"id":"pembrolizumab-eu","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Fatigue"},{"rate":"15–25","effect":"Diarrhea"},{"rate":"10–20","effect":"Nausea"},{"rate":"10–15","effect":"Decreased appetite"},{"rate":"3–5","effect":"Immune-mediated pneumonitis"},{"rate":"2–4","effect":"Immune-mediated colitis"},{"rate":"1–3","effect":"Immune-mediated hepatitis"},{"rate":"5–10","effect":"Immune-mediated endocrinopathy (thyroiditis, adrenalitis)"},{"rate":"8–15","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pembrolizumab binds to programmed death receptor 1 (PD-1) on T cells, preventing interaction with its ligands PD-L1 and PD-L2 on tumor cells. This blockade releases the 'brakes' on the immune system, restoring T cell activation, proliferation, and anti-tumor function. By reinvigorating exhausted T cells, pembrolizumab enables durable immune responses against cancer.","oneSentence":"Pembrolizumab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:50.915Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma"},{"name":"Non-small cell lung cancer (NSCLC)"},{"name":"Head and neck squamous cell carcinoma"},{"name":"Hodgkin lymphoma"},{"name":"Urothelial carcinoma"},{"name":"Gastric cancer"},{"name":"Cervical cancer"},{"name":"Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors"}]},"trialDetails":[{"nctId":"NCT06687369","phase":"PHASE3","title":"A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)","status":"RECRUITING","sponsor":"mAbxience Research S.L.","startDate":"2024-12-30","conditions":"Non Squamous Non Small Cell Lung Cancer","enrollment":726},{"nctId":"NCT06159790","phase":"PHASE3","title":"A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)","status":"SUSPENDED","sponsor":"Sandoz","startDate":"2024-04-29","conditions":"Metastatic NSCLC","enrollment":218},{"nctId":"NCT06153238","phase":"PHASE1","title":"A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sandoz","startDate":"2024-05-15","conditions":"Melanoma","enrollment":322},{"nctId":"NCT06311721","phase":"PHASE3","title":"A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2024-09-09","conditions":"Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer","enrollment":315},{"nctId":"NCT06280196","phase":"PHASE3","title":"A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC","status":"TERMINATED","sponsor":"Bio-Thera Solutions","startDate":"2024-07-19","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":162},{"nctId":"NCT06268613","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2024-01-16","conditions":"Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage IIIA","enrollment":163},{"nctId":"NCT06939595","phase":"PHASE3","title":"A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer","status":"RECRUITING","sponsor":"Celltrion","startDate":"2025-01-30","conditions":"Non Squamous Non Small Cell Lung Cancer","enrollment":606},{"nctId":"NCT06847334","phase":"PHASE3","title":"A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-04-27","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":772},{"nctId":"NCT06111196","phase":"PHASE1","title":"Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2023-11-05","conditions":"Healthy Male Subjects","enrollment":59}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Keytruda®"],"phase":"phase_3","status":"active","brandName":"Pembrolizumab (EU)","genericName":"Pembrolizumab (EU)","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pembrolizumab is a programmed cell death protein 1 inhibitor used to treat various conditions, including non-squamous non-small cell lung cancer, melanoma, and metastatic non-small cell lung cancer. It is classified as an inhibitor and is an antibody-based treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}